- Newsletter
- March 2025
- 3 Pages
Europe
From €125EUR$131USD£105GBP
- Report
- January 2022
- 220 Pages
Global
From €3543EUR$3,712USD£2,968GBP
Humira is a biologic drug used to treat psoriasis, a chronic skin condition. It is a monoclonal antibody that works by blocking the action of tumor necrosis factor (TNF), a protein that plays a role in inflammation. Humira is the most widely prescribed biologic drug for psoriasis, and is used to treat moderate to severe cases of the condition. It is administered via subcutaneous injection, and is typically used in combination with other treatments such as topical medications and phototherapy.
Humira is a part of a larger market of psoriasis drugs, which includes other biologics such as Enbrel and Remicade, as well as traditional treatments such as topical corticosteroids and vitamin D analogues. The market is highly competitive, with many companies vying for a share of the market.
Some of the companies in the psoriasis drug market include AbbVie, Amgen, Janssen, Novartis, Pfizer, and UCB. Show Less Read more